--- title: "Amgen Inc. $AMGN Shares Purchased by Simplicity Wealth LLC" type: "News" locale: "en" url: "https://longbridge.com/en/news/296332019.md" description: "Simplicity Wealth LLC increased its stake in Amgen Inc. by 122.5% in Q2, holding 10,539 shares valued at $3.8 million. Other institutions like High Note Wealth and TAGStone Capital also raised positions. Amgen recently reported strong Q2 earnings of $6.29 EPS, beating estimates, with revenue up 9.5% YoY. The company announced a $2.52 quarterly dividend. Analysts have mixed views, with RBC raising its price target to $400 while Bank of America lowered it to $317." datetime: "2026-08-19T09:29:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296332019.md) - [en](https://longbridge.com/en/news/296332019.md) - [zh-HK](https://longbridge.com/zh-HK/news/296332019.md) --- # Amgen Inc. $AMGN Shares Purchased by Simplicity Wealth LLC Simplicity Wealth LLC lifted its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 122.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 10,539 shares of the medical research company's stock after purchasing an additional 5,802 shares during the quarter. Simplicity Wealth LLC's holdings in Amgen were worth $3,816,000 as of its most recent SEC filing. - Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All Several other hedge funds and other institutional investors also recently bought and sold shares of the business. High Note Wealth LLC lifted its stake in Amgen by 5.8% during the 4th quarter. High Note Wealth LLC now owns 508 shares of the medical research company's stock valued at $166,000 after acquiring an additional 28 shares during the period. TAGStone Capital Inc. raised its holdings in shares of Amgen by 0.7% during the fourth quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company's stock worth $1,351,000 after purchasing an additional 28 shares during the last quarter. Verus Capital Partners LLC raised its holdings in shares of Amgen by 2.3% during the fourth quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company's stock worth $403,000 after purchasing an additional 28 shares during the last quarter. Destination Wealth Management lifted its position in Amgen by 2.1% during the fourth quarter. Destination Wealth Management now owns 1,393 shares of the medical research company's stock valued at $456,000 after purchasing an additional 29 shares during the period. Finally, Breakwater Capital Group boosted its holdings in Amgen by 1.4% in the first quarter. Breakwater Capital Group now owns 2,039 shares of the medical research company's stock valued at $717,000 after purchasing an additional 29 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company's stock. ## Amgen Trading Up 1.4% Shares of Amgen stock opened at $425.28 on Wednesday. The firm has a 50-day simple moving average of $373.66 and a two-hundred day simple moving average of $360.06. The company has a market cap of $229.92 billion, a P/E ratio of 26.43, a price-to-earnings-growth ratio of 3.86 and a beta of 0.41. Amgen Inc. has a fifty-two week low of $269.77 and a fifty-two week high of $427.39. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. - 3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, beating analysts' consensus estimates of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The firm had revenue of $10.05 billion for the quarter, compared to analysts' expectations of $9.43 billion. During the same period last year, the firm earned $6.02 EPS. The company's quarterly revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities analysts predict that Amgen Inc. will post 22.78 earnings per share for the current fiscal year. ## Amgen Announces Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Friday, August 21st. Amgen's dividend payout ratio (DPR) is presently 62.65%. ## Wall Street Analysts Forecast Growth - 5 Healthcare Names to Watch as Sector Rotation Is in Full Swing Several equities research analysts have weighed in on the company. Royal Bank Of Canada increased their price target on Amgen from $370.00 to $400.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 5th. Daiwa Securities Group decreased their price objective on Amgen from $410.00 to $390.00 and set an "outperform" rating for the company in a report on Wednesday, May 13th. Piper Sandler restated an "overweight" rating on shares of Amgen in a research note on Friday, June 12th. The Goldman Sachs Group set a $389.00 target price on Amgen in a report on Friday, June 5th. Finally, Bank of America boosted their price target on Amgen from $312.00 to $317.00 and gave the company an "underperform" rating in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, fifteen have given a Hold rating and three have given a Sell rating to the company's stock. According to MarketBeat, Amgen currently has an average rating of "Hold" and a consensus target price of $375.93. **Get Our Latest Analysis on AMGN** ## Insider Buying and Selling In other news, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares in the company, valued at $2,951,854.40. This trade represents a 28.81% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Rachna Khosla sold 1,252 shares of Amgen stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the sale, the senior vice president directly owned 6,404 shares in the company, valued at $2,666,817.72. This represents a 16.35% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 6,222 shares of company stock valued at $2,540,926 over the last 90 days. Company insiders own 0.85% of the company's stock. ## Amgen News Roundup Here are the key news stories impacting Amgen this week: - Positive Sentiment: Amgen’s recent results reinforced its growth narrative: quarterly revenue rose 9.5% year over year to $10.05 billion, while adjusted earnings of $6.29 per share exceeded consensus by $0.67. Management’s fiscal 2026 EPS guidance of $22.30–$23.50 also supports the bullish outlook. Amgen Results Put Growth Back in Focus - Positive Sentiment: A completed Phase 1 study comparing two evolocumab formulations provides continued support for Amgen’s cholesterol franchise. Evolocumab, marketed as Repatha, is an important commercial product, and formulation work could help support its future development and patient use. Amgen’s Evolocumab Formulation Study - Positive Sentiment: Growth-focused analysis from Zacks highlights Amgen’s earnings profile and potential for continued performance, adding to the favorable investor narrative. Why Amgen Is a Strong Growth Stock - Neutral Sentiment: Cantor Fitzgerald raised its Amgen price target to $400 but retained a Neutral rating. Mizuho also maintained Neutral while lifting its target to $352, indicating that analysts see some fundamental improvement but believe the recent rally has exceeded their valuation expectations. - Negative Sentiment: Amgen exercised its right to terminate a partnership with TScan Therapeutics, removing a collaboration from TScan’s pipeline. While the direct financial effect on Amgen is unclear, the termination may raise questions about partnership prioritization or the development prospects of the related program. TScan Therapeutics Faces Loss of Key Amgen Partnership ## About Amgen (Free Report) Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients. Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease. ## Read More - Five stocks we like better than Amgen - The AI Boom Is Turning This Cable Maker Into a Stock to Watch - A Star Investor Just Trimmed Amazon—Here's What It means - Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look - Home Depot Analysts See a Path to $375 and Beyond **Want to see what other hedge funds are holding AMGN?** Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report). _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Amgen Right Now? Before you consider Amgen, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list. While Amgen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md) - [RY.US](https://longbridge.com/en/quote/RY.US.md) - [8601.JP](https://longbridge.com/en/quote/8601.JP.md) - [PIPR.US](https://longbridge.com/en/quote/PIPR.US.md) - [GS.US](https://longbridge.com/en/quote/GS.US.md) - [BAC.US](https://longbridge.com/en/quote/BAC.US.md) - [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md) - [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md) - [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md) - [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md) - [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md) - [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md) - [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md) - [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md) - [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md) - [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md) - [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md) - [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md) - [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md) - [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md) - [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md) - [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md) - [8648.JP](https://longbridge.com/en/quote/8648.JP.md) ## Related News & Research - [Amgen Inc. $AMGN Shares Bought by Bridgewater Advisors Inc.](https://longbridge.com/en/news/296072511.md) - [Hussman Strategic Advisors Inc. Has $3.04 Million Stock Position in Amgen Inc. $AMGN](https://longbridge.com/en/news/295999249.md) - [Simplicity Wealth LLC Invests $908,000 in BlackRock $BLK](https://longbridge.com/en/news/296090579.md) - [Argus Issues Positive Forecast for Amgen (NASDAQ:AMGN) Stock Price](https://longbridge.com/en/news/296364491.md) - [Abner Herrman & Brock LLC Decreases Stock Holdings in Amgen Inc. $AMGN](https://longbridge.com/en/news/295293655.md)